Can bevacizumab prolong survival for glioblastoma patients through multiple lines of therapy?

Future Oncology

Volumn 10, Issue 7, 2014, Pages 1137-1145

  Brandes, Alba A ^a   Mason, Warren ^b   Pichler, Josef ^c   Nowak, Anna K ^d   Gil, Miguel ^e   Saran, Frank ^f   Revil, Cedric ^g   Lutiger, Beatrix ^g   Carpentier, Antoine F ^h,i  

^a BELLARIA HOSPITAL   (Italy)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c KEPLER UNIVERSITY HOSPITAL   (Austria)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^f Cancer Centre London   (United Kingdom)

^g F HOFFMANN LA ROCHE LTD   (Switzerland)

^h AVICENNE HOSPITAL   (France)

ⁱ UNIVERSITÉ PARIS 13   (France)

Author keywords

bevacizumab; clinical trial; glioblastoma; multiple lines; newly diagnosed; Phase IIIb; progression; recurrent; trials in progress; vascular endothelial growth factor; VEGF

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; ETOPOSIDE; FOTEMUSTINE; IRINOTECAN; LOMUSTINE; PLACEBO; TEMOZOLOMIDE; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY;

ANTIANGIOGENIC THERAPY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL EVALUATION; GLIOBLASTOMA; HEALTH CARE QUALITY; HUMAN; METASTATIC COLORECTAL CANCER; MULTICENTER STUDY (TOPIC); MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SALVAGE THERAPY; BRAIN NEOPLASMS; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOUBLE BLIND PROCEDURE; PATHOLOGY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BRAIN NEOPLASMS; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; GLIOBLASTOMA; HUMANS; SURVIVAL RATE;

EID: 84903194653     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.14.75     Document Type: Article

References (55)

1. Bennouna J, Sastre J, Arnold D et al. Continuation of bevacizumab after frst progression in metastatic colorectal cancer (ML18147): a randomised Phase 3 trial. Lancet Oncol. 14, 29-37 (2013).
2. Ohgaki H, Dessen P, Jourde B et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res. 64, 6892-6899 (2004)
3. Central Brain Tumor Registry of the United States (CBRTUS). www.cbtrus.org
4. Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised Phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10, 459-466 (2009).
5. Stupp R, Tonn JC, Brada M et al. High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 21(Suppl. 5), v190-v193 (2010).
6. Franceschi E, Tosoni A, Girardi F et al. Bevacizumab in brain tumors: ready for primetime? Future Oncol. 5, 1183-1184 (2009).
7. NCCN Guidelines Central Nervous System Cancers. Version 1.2012. www.nccn.org/professionals/physician-gls/pdf/cns.pdf
8. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987-996 (2005).
9. Brandes AA, Tosoni A, Franceschi E et al. Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a Phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Cancer Chemother. Pharmacol. 64, 769-775 (2009).
10. Brem S, Folkman J, Cotran R. Tumor angiogenesis-quantitative method for histologic grading. J. Natl Cancer Inst. 48, 347-356 (1972).
11. Chaudhry IH, O'Donovan DG, Brenchley PEC et al. Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas. Histopathology 39, 409-415 (2001).
12. Salmaggi A, Eoli M, Frigerio S et al. Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma. J. Neurooncol. 62, 297-303 (2003).
13. Wen PY, Brandes AA. Treatment of recurrent high-grade gliomas. Curr. Opin. Neurol. 22, 657-664 (2009).
14. Cohen MH, Shen YL, Keegan P et al. FDA drug approval summary: bevacizumab (Avastin®) as treatment of recurrent glioblastoma multiforme. Oncologist 14, 1131-1138 (2009).
15. Friedman HS, Prados MD, Wen PY et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 27, 4733-4740 (2009).
16. Kreisl TN, Kim L, Moore K et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J. Clin. Oncol. 27, 740-745 (2009).
17. Vredenburgh JJ, Desjardins A, Herndon JE et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin. Oncol. 25, 4722-4729 (2007).
18. Soffetti R, Trevisan E, Ruda R et al. Phase II trial of bevacizumab with fotemustine in recurrent glioblastoma: fnal results of a multicenter study of AINO (Italian Association of Neuro-Oncology). Neuro Oncol. 29(15), 56-57 (2011).
19. Desjardins A, Reardon DA, Coan A et al. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer 118, 1302-1312 (2012).
20. Reardon DA, Desjardins A, Vredenburgh JJ et al. Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a Phase II study. Br. J. Cancer 101, 1986-1994 (2009).
21. Sepulveda JM, Belda C, Gil M et al. Bevacizumab in combination with TMZ in patients with recurrent GBM: fnal OS and PFS analysis. Presented at: 2013 American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA, 31 May-4 June 2013.
22. Maree K, Simes J, Wheeler H et al. A randomised Phase II study of carboplatin and bevacizumab in recurrent glioblastoma multiforme (CABARET). Presented at: 2013 American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA, 31 May-4 June 2013.
23. Taal W, Oosterkamp HM, WalenKamp L et al. A randomized Phase II study on bevacizumab versus bevacizumab plus lomustine versus lomustine single agent in recurrent glioblastoma: the Dutch BELOB study. Presented at: 2013 American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA, 31 May-4 June 2013.
24. Selfridge J, Piccioni DE, Zurayk M et al. Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished effcacy. Presented at: 2012 Annual Scientifc Meeting of the Society for Neuro-Oncology. Washington DC, USA, 15-18 November 2012.
25. Lai A, Tran A, Nghiemphu PL et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J. Clin. Oncol. 29, 142-148 (2011).
26. Narayana A, Gruber D, Kunnakkat S et al. A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma. J. Neurosurg. 116, 341-345 (2012).
27. Gilbert MR, Dignam JJ, Armstrong TC et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N. Engl. J. Med. 370, 699-708 (2014).
28. Chinot OL, Wick W, Mason W et al. Bevacizumab plus radiotherapy/ temozolomide for newly diagnosed glioblastoma. N. Engl. J. Med. 370, 709-722 (2014).
29. Mancuso MR, Davis R, Norberg SM et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J. Clin. Invest. 116, 2610-2621 (2006).
30. Zuniga RM, Torcuator R, Jain R et al. Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma. J. Neuro-Oncol. 99, 237-242 (2010).
31. Miles D, Harbeck N, Escudier B et al. Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized Phase III trials. J. Clin. Oncol. 29, 83-88 (2011).
32. Cobleigh MA, Langmuir VK, Sledge GW et al. A Phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin. Oncol. 30, 117-124 (2003).
33. Mellor HR, Callaghan R. Resistance to chemotherapy in cancer: a complex and integrated cellular response. Pharmacol. 81, 275-300 (2008).
34. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 8, 592-603 (2008).
35. Giantonio BJ. Goldie-Coldman and bevacizumab beyond disease progression. Nat. Rev. Clin. Oncol. 6, 311-312 (2009).
36. Lu KV, Bergers G. Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma. CNS Oncol. 2, 49-65 (2013).
37. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58-62 (2005).
38. Taylor J, Gerstner ER. Anti-angiogenic therapy in high-grade glioma (treatment and toxicity). Curr. Treat. Options Neurol. 5(3), 328-337 (2013).
39. Norden AD, Drappatz J, Muzikansky A et al. An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma. J. Neurooncol. 92, 149-155 (2009).
40. Brandes AA, Tosoni A, Spagnolli F et al. Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology. Neuro Oncol. 10, 361-367 (2008).
41. Brandes AA, Franceschi E, Tosoni A et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J. Clin. Oncol. 26, 2192-2197 (2008).
42. Reardon DA, Desjardins A, Peters KB et al. Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. Cancer 117, 5351-5358 (2011).
43. Reardon DA, Desjardins A, Peters K et al. Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. J. Neurooncol. 103, 371-379 (2011).
44. Quant EC, Norden AD, Drappatz J et al. Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. Neuro Oncol. 11, 550-555 (2009).
45. Iwamoto FM, Abrey LE, Beal K et al. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 73, 1200-1206 (2009).
46. Norden AD, Young GS, Setayesh K et al. Bevacizumab for recurrent malignant gliomas-effcacy, toxicity, and patterns of recurrence. Neurology 70, 779-787 (2008).
47. Torcuator RG, Thind R, Patel M et al. The role of salvage reirradiation for malignant gliomas that progress on bevacizumab. J. Neurooncol. 97, 401-407.
48. Reardon DA, Herndon JE, Peters KB et al. Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients. Br. J. Cancer 107, 1481-1487 (2012).
49. Brandes AA, Franceschi E. New agents and new end points for recurrent gliomas. J. Clin. Oncol. 29, e245-e246 (2011).
50. Brandes AA, Franceschi E, Gorlia T et al. Appropriate end-points for right results in the age of antiangiogenic agents: future options for Phase II trials in patients with recurrent glioblastoma. Eur. J. Cancer 48, 896-903 (2012).
51. Batchelor T T, Sorensen AG, di Tomaso E et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11, 83-95 (2007).
52. Chen W, Delaloye S, Silverman DHS et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [F-18] fuorothymidine positron emission tomography: a pilot study. J. Clin. Oncol. 25, 4714-4721 (2007).
53. Wen PY, Macdonald DR, Reardon DA et al. Updated response assessment criteria for high-grade gliomas: response assessment in Neuro-Oncology Working Group. J. Clin. Oncol. 28, 1963-1972 (2010).
54. Stupp R, Hottinger AF, van den Bent MJ et al. Frequently asked questions in the medical management of high-grade glioma: a short guide with practical answers. Ann. Oncol. 19(Suppl. 7), vii209-vii216 (2008).
55. Girardi F, Franceschi E, Brandes AA. Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies. Oncologist 15, 683-694 (2010).